32 8 001 28 80
Full-time employees: 3,035
|Mr. Rafael Padilla||CEO & Exec. Director||621.53k||N/A||1978|
|Ms. Karin de Jong||CFO & Exec. Director||410.14k||N/A||1979|
|Ms. Vera Bakker||Chief Operating Officer||N/A||N/A||1972|
|Karen Berg||Global Investor Relations Mang.||N/A||N/A||N/A|
|Mr. Johan Verlinden||Head of Legal, Mergers & Acquisitions||N/A||N/A||N/A|
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
Fagron NV’s ISS governance QualityScore as of 1 March 2023 is 3. The pillar scores are Audit: 5; Board: 4; Shareholder rights: 1; Compensation: 5.